There was little difference in the ratios of BsAb-BCMA dimer:tumor cell between the dosing schedules, as shown in Supplementary Fig. 5c, suggesting that most BCMA receptors were engaged with BsAb in a dimer complex. The gene discussed is TNFRSF17; the disease is neoplasm.